Fig. 5.

Dual targeting of p110α/β abrogates anti-estrogen-resistant growth of PTEN-deficient, ER+ breast tumors. A) Lysates of ZR75-1/FR tumors from mice treated with fulv, then harvested after 3 d of treatment with PI3K inhibitors were analyzed by immunoblot. B) Tumor volumes are shown as % baseline (mean + SEM). *p≤0.01 by non-linear mixed modeling compared to “Vehicle/Fulv” group, unless otherwise indicated with brackets. C) Tumors were harvested after 3 d or 10 wk of treatment with fulv/PI3K inhibitors (or 4 wk for Vehicle/Fulv-treated group) and analyzed as in (A). D-E) Tumors were analyzed by (D) IHC for Ki67 or (E) TUNEL. Horizontal red bars indicate mean values. *p≤0.05 by Bonferonni post-hoc test compared to 3-day Vehicle/Fulv controls unless otherwise indicated with brackets.